RESUMEN
At the time of publication, radiopharmaceuticals labelled with thorium-227 are in clinical trials in Europe for the treatment of various types of cancer. In part I of this two-part series the primary standardisation of an aqueous solution of 227Th was reported. In part II, the activity derived from the recommended absolute γ-ray emission intensities have been compared to that from the primary standardisation techniques. This comparison showed a negative bias of 4% in the determined activity per unit mass with an 11% spread in the activities determined for the eight most intense γ-ray emissions (Iγ > 1%) from the 227Th α decay. Using the standardised 227Th, measurements of the characteristic γ-ray emissions from the 223Ra excited states were made using a calibrated HPGe γ-ray spectrometer. This has enabled the absolute intensities of 70 γ ray emissions from the 227Th α-decay to be experimentally determined. A significant improvement over the precision of the recommended normalisation scaling factor has been made, with a value of 12.470 (35) % determined. Typically, the precision of the intensities has been improved by an order of magnitude or greater than current recommended values. The correlation matrices for pairs of the most intense γ-ray emission intensities are presented.
Asunto(s)
Radiofármacos/uso terapéutico , Torio/uso terapéutico , Partículas alfa/uso terapéutico , Calibración , Rayos gamma/uso terapéutico , Humanos , Neoplasias/radioterapia , Radioinmunoterapia/métodos , Radioinmunoterapia/normas , Radiofármacos/normas , Radio (Elemento)/química , Estándares de Referencia , Conteo por Cintilación , Espectrometría gamma , Torio/normasRESUMEN
Thorium-227 is a potential therapeutic radionuclide for applications in targeted α-radioimmunotherapy for the treatment of various types of cancer. To provide nuclear medicine departments involved in Phase I clinical trials traceability to the SI unit of radioactivity (Bq), a standardisation of a radiochemically pure 227Th aqueous solution has been performed at the National Physical Laboratory. This was achieved via two primary liquid scintillation (LS) techniques -4π(LS)-γ digital coincidence counting (DCC) and 4π LS counting. These absolute techniques were supported by the indirect determination of the 227Th activity via the measurement of the ingrowth and decay rate of the decay progeny by both ionisations chambers and high purity germanium (HPGe) gamma-ray spectrometry. The results of the primary techniques were found to be consistent, both with each other (zeta score =â¯1.1) and to the decay progeny ingrowth measurements. An activity per unit mass of 20.726 (51) kBq g-1 was determined for the solution. A procedure has been developed that provided an effective separation of the 227Th from its decay progeny, which was shown by the effective time zero of the 227Th-223Ra nuclear chronometer measured by HPGe gamma-ray spectrometry.
Asunto(s)
Radiofármacos/normas , Torio/normas , Partículas alfa/uso terapéutico , Germanio , Semivida , Humanos , Neoplasias/radioterapia , Radioinmunoterapia/métodos , Radioinmunoterapia/normas , Radiometría/instrumentación , Radiofármacos/análisis , Radiofármacos/uso terapéutico , Estándares de Referencia , Conteo por Cintilación/métodos , Espectrometría gamma , Torio/análisis , Torio/uso terapéuticoRESUMEN
This guideline is a prerequisite for the quality management in the treatment of non-Hodgkon-lymphomas in patients with relapsed or refractory follicular lymphoma after rituximab therapy and as consolidation therapy after first remission following CHOP like treatment using radioimmunotherapy. It is based on an interdisciplinary consensus and contains background information and definitions as well as specified indications and detailed contraindications of treatment. Essential topics are the requirements for institutions performing the therapy. For instance, presence of an expert for medical physics, intense cooperation with all colleagues committed to treatment of lymphomas, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how treatment has to be carried out technically. Here, quality control and documentation of labelling are of great importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with those colleagues (hemato-oncologists) who propose, in general, radioimmunotherapy under consideration of the development of the disease.
Asunto(s)
Antígenos CD2/inmunología , Linfoma de Células B/inmunología , Linfoma de Células B/radioterapia , Medicina Nuclear/normas , Garantía de la Calidad de Atención de Salud/normas , Oncología por Radiación/normas , Radioinmunoterapia/normas , Alemania , HumanosRESUMEN
Only a handful of radiolabeled antibodies (Abs) have gained US Food and Drug Administration (FDA) approval for use in clinical oncology, including four immunodiagnostic agents and two targeted radioimmunotherapeutic agents. Despite the advent of nonimmunogenic Abs and the availability of a diverse library of radionuclides, progress beyond early Phase II radioimmunotherapy (RIT) studies in solid tumors has been marginal. Furthermore, [18F]fluorodeoxyglucose continues to dominate the molecular imaging domain, underscored by a decade-long absence of any newly approved Ab-based imaging agent (none since 1996). Why has the development of clinically successful Abs for RIT been limited to lymphoma? What obstacles must be overcome to allow the FDA approval of immuno-positron emission tomography (immuno-PET) imaging agents? How can we address the unique challenges that have thus far prevented the introduction of Ab-based imaging agents and therapeutics for solid tumors? Many poor decisions have been made regarding radiolabeled Abs, but useful insight can be gained from these mistakes. The following review addresses the physical, chemical, biological, clinical, regulatory and financial limitations that impede the progress of this increasingly important class of drugs.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Aprobación de Drogas , Radioinmunodetección/tendencias , Radioinmunoterapia/tendencias , Radiofármacos/uso terapéutico , Radioinmunodetección/normas , Radioinmunoterapia/normas , Radiofármacos/normas , Estados Unidos , United States Food and Drug AdministrationRESUMEN
BACKGROUND: In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine. PURPOSE: The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Linfoma de Células B/radioterapia , Medicina Nuclear/normas , Radioinmunoterapia/normas , Humanos , Pautas de la Práctica en Medicina/normas , Radiofármacos/normas , Radiofármacos/uso terapéuticoAsunto(s)
Anticuerpos/sangre , Médula Ósea/metabolismo , Modelos Cardiovasculares , Radiometría/métodos , Radiometría/normas , Dosificación Radioterapéutica/normas , Medición de Riesgo/métodos , Adulto , Anciano , Algoritmos , Anticuerpos/uso terapéutico , Femenino , Humanos , Radioisótopos de Yodo/sangre , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Radioinmunoterapia/métodos , Radioinmunoterapia/normas , Técnica de Dilución de Radioisótopos , Radioisótopos/sangre , Radioisótopos/farmacocinética , Radioisótopos/uso terapéutico , Radiofármacos/sangre , Radiofármacos/farmacocinética , Radiofármacos/uso terapéutico , Renio/sangre , Renio/farmacocinética , Renio/uso terapéutico , Factores de Riesgo , Estados UnidosRESUMEN
This guideline is a prerequisite for the quality management in the treatment of non-Hodgkin-lymphomas using radioimmunotherapy. It is based on an interdisciplinary consensus and contains background information and definitions as well as specified indications and detailed contraindications of treatment. Essential topics are the requirements for institutions performing the therapy. For instance, presence of an expert for medical physics, intense cooperation with all colleagues committed to treatment of lymphomas, and a certificate of instruction in radiochemical labelling and quality control are required. Furthermore, it is specified which patient data have to be available prior to performance of therapy and how the treatment has to be carried out technically. Here, quality control and documentation of labelling are of greatest importance. After treatment, clinical quality control is mandatory (work-up of therapy data and follow-up of patients). Essential elements of follow-up are specified in detail. The complete treatment inclusive after-care has to be realised in close cooperation with those colleagues (haematology-oncology) who propose, in general, radioimmunotherapy under consideration of the development of the disease.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos CD20/sangre , Linfoma de Células B/radioterapia , Linfoma Folicular/radioterapia , Radioinmunoterapia/normas , Anticuerpos Monoclonales/farmacocinética , Anticuerpos Monoclonales de Origen Murino , Antígenos CD/sangre , Humanos , Linfoma de Células B/sangre , Linfoma Folicular/sangre , Control de Calidad , Dosificación Radioterapéutica , Rituximab , Distribución TisularRESUMEN
UNLABELLED: Standardization of marrow dosimetry is of considerable importance when estimating dose-response for a multicentered clinical trial involving radionuclide therapy. However, it is only within the past five years that the intercomparison of marrow dosimetry results among separate clinical trials that use the same agent has become scientifically feasible. In this work, we have analyzed reported marrow dosimetry results from radioimmunotherapy trials and recalculated marrow absorbed doses at a central facility using a standard blood model with patient-specific source data. The basic approach used in the American Association of Physicists in Medicine (AAPM)/Sgouros marrow dosimetry methodology was common to calculation performed at all participating institutions, including the central facility. Differences in dose estimates associated with starting assumptions and the exact implementation of the AAPM/Sgouros calculation methodology used by the source institutions and the central facility were quantified and compared. METHODS: Data from 22 patients enrolled in radiolabeled antibody clinical trials were randomly selected from 7 participating institutions for the assessment of marrow dose. The analysis was restricted to those patients who were treated with 131I- or 186Re-labeled antibody and had no marrow involvement. Calculation of bone marrow dose at each participating institution was unique to the trial or institution, but all used some form of the AAPM/Sgouros blood model approach. The central facility adopted a marrow dosimetry model based on the AAPM/Sgouros model for radiolabeled antibodies using the standard MIRD approach to the remainder-of-body contribution. A standardized approach to account for variations in patient mass was used for the remainder-of-body component. To simplify clinical implementation, regional marrow uptake and time-dependent changes in the marrow-to-blood concentration ratio were not included. Methods of formatting the collection of standard datasets useful in defining dose-response parameters are also presented. RESULTS: Bone marrow doses were calculated according to the method described for each of the 22 patients based on the patient-specific data supplied by the participating institutions. These values were then individually compared with the marrow doses originally reported by each institution. Comparison of the two calculation methods was expressed as a ratio of the marrow doses for each patient. The mean ratio for the dose estimates at the participating institution calculation compared with the central laboratory value was 0.920 +/- 0.259 (mean +/- SD), with a range from 0.708 to 1.202. CONCLUSION: The independent use of the AAPM/Sgouros method blood model approach to marrow dosimetry has brought these dose estimates to within 30% of the results obtained centrally compared with substantially higher uncertainties reported previously. Variations in calculation methodology or initial assumptions adopted by individual institutions may still contribute significant uncertainty to dose estimates, even when the same data are used as a starting point for the calculation comparison shown here. A clinically relevant, standard method for marrow dosimetry for radiolabeled antibodies is proposed as a benchmark for intercomparison purposes. A parameter sensitivity analysis and a summary discussion of the use of this model for potentially improving dose-response data correlation are also presented.
Asunto(s)
Anticuerpos/sangre , Médula Ósea/metabolismo , Modelos Cardiovasculares , Radiometría/métodos , Radiometría/normas , Dosificación Radioterapéutica/normas , Medición de Riesgo/métodos , Adulto , Anciano , Algoritmos , Anticuerpos/uso terapéutico , Femenino , Humanos , Radioisótopos de Yodo/sangre , Radioisótopos de Yodo/farmacocinética , Radioisótopos de Yodo/uso terapéutico , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Radioinmunoterapia/métodos , Radioinmunoterapia/normas , Técnica de Dilución de Radioisótopos , Radioisótopos/sangre , Radioisótopos/farmacocinética , Radioisótopos/uso terapéutico , Radiofármacos/sangre , Radiofármacos/farmacocinética , Radiofármacos/uso terapéutico , Renio/sangre , Renio/farmacocinética , Renio/uso terapéutico , Factores de Riesgo , Estados UnidosRESUMEN
OBJECTIVE: Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of the immune system, with more than 53,900 new cases diagnosed in 2002. Conventional cancer therapies cure many, but not the majority of, cases of the aggressive forms of NHL, and the more indolent and follicular forms of the disease that affect nearly half of all patients with NHL are considered incurable. In the absence of cure or survival benefits, treatments such as radioimmunotherapy that induce remission and prolong time off therapy are considered valuable. (90)Y-Ibritumomab tiuxetan recently became the first radioimmunotherapy agent to be approved for commercial use by the U.S. Food and Drug Administration. After reading this article, the nuclear medicine technologist should be able to understand the incidence and prevalence of NHL, describe the ibritumomab tiuxetan therapy protocol, explain specific infusion techniques for this protocol, list acquisition parameters after injection of (111)In-ibritumomab tiuxetan, and describe specific safety techniques to keep risk as low as reasonably achievable while performing the therapy protocol.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Linfoma de Células B/radioterapia , Radioinmunoterapia/métodos , Planificación de la Radioterapia Asistida por Computador/métodos , Humanos , Linfoma de Células B/diagnóstico por imagen , Recurrencia Local de Neoplasia , Cuidados Paliativos/métodos , Protección Radiológica/métodos , Radioinmunoterapia/normas , Cintigrafía , Radiofármacos/uso terapéutico , Dosificación Radioterapéutica , Radioisótopos de Itrio/uso terapéuticoRESUMEN
Radioimmunotherapy with radiolabeled anti-CD20 antibodies is a promising new treatment approach for low-grade non-Hodgkin's lymphoma. However, the administration of radiolabeled antibodies presents some added complexity. At the University of Nebraska Medical Center (Omaha, NE), an institutional model has been developed that ensures the efficient and safe delivery of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, South San Francisco, CA and GlaxoSmithKline, Philadelphia, PA). An integrated, multidisciplinary treatment team is responsible for managing all aspects of treatment. Using this model, it is possible to administer tositumomab and iodine I 131 tositumomab safely and effectively in the outpatient setting. Patients can usually be released immediately after treatment. Guidelines and instructions for patient release have been developed and validated and are provided herein. These instructions ensure that radiation exposure of family members and caregivers who are exposed to the patient is maintained as low as reasonably achievable and well within regulatory limits.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Antineoplásicos/administración & dosificación , Radioisótopos de Yodo/administración & dosificación , Linfoma no Hodgkin/radioterapia , Radioinmunoterapia/normas , Antígenos CD20 , Humanos , Alta del Paciente , Radioinmunoterapia/métodos , Dosificación RadioterapéuticaRESUMEN
BACKGROUND: The approval of monoclonal antibodies (MAbs) as antibody-targeted therapy in the management of patients with hematologic malignancies has led to new treatment options for this group of patients. The ability to target antibodies to novel functional receptors can increase their therapeutic efficacy. METHODS: The authors reviewed improvements in MAb design to enhance their effectiveness over the existing therapeutic MAb currently approved for treating hematologic malignancies. RESULTS: Three classes of therapeutic MAbs showing promise in human clinical trials for treatment of hematologic malignancies include unconjugated MAb, drug conjugates in which the antibody preferentially delivers a potent cytotoxic drug to the tumor, and radioactive immunotherapy in which the antibody delivers a sterilizing dose of radiation to the tumor. CONCLUSIONS: A better appreciation of how MAbs are metabolized in the body and localized to tumors is resulting in the development of new antibody constructs with improved biodistribution profiles.
Asunto(s)
Anticuerpos Biespecíficos/inmunología , Anticuerpos Biespecíficos/uso terapéutico , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/uso terapéutico , Neoplasias Hematológicas/terapia , Animales , Ensayos Clínicos Fase III como Asunto , Terapia Combinada , Quimioterapia , Predicción , Neoplasias Hematológicas/inmunología , Reacción Huésped-Injerto/inmunología , Humanos , Sistema Inmunológico/efectos de los fármacos , Sistema Inmunológico/inmunología , Estudios Multicéntricos como Asunto , Radioinmunoterapia/normas , Resultado del Tratamiento , Estados Unidos/epidemiología , United States Food and Drug AdministrationRESUMEN
The conditioning regimen prior to stem cell transplantation in 36 patients with high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) was intensified by treating patients with a rhenium 188-labeled anti-CD66 monoclonal antibody. Dosimetry was performed prior to therapy, and a favorable dosimetry was observed in all cases. Radioimmunotherapy with the labeled antibody provided a mean of 15.3 Gy of additional radiation to the marrow; the kidney was the normal organ receiving the highest dose of supplemental radiation (mean 7.4 Gy). Radioimmunotherapy was followed by standard full-dose conditioning with total body irradiation (12 Gy) or busulfan and high-dose cyclophosphamide with or without thiotepa. Patients subsequently received a T-cell-depleted allogeneic graft from a HLA-identical family donor (n = 15) or an alternative donor (n = 17). In 4 patients without an allogeneic donor, an unmanipulated autologous graft was used. Infusion-related toxicity due to the labeled antibody was minimal, and no increase in treatment-related mortality due to the radioimmunoconjugate was observed. Day +30 and day +100 mortalities were 3% and 6%, respectively, and after a median follow-up of 18 months treatment-related mortality was 22%. Late renal toxicity was observed in 17% of patients. The relapse rate of 15 patients undergoing transplantation in first CR (complete remission) or second CR was 20%; 21 patients not in remission at the time of transplantation had a 30% relapse rate. (Blood. 2001;98:565-572)
Asunto(s)
Antígenos CD/inmunología , Antígenos de Diferenciación/inmunología , Leucemia Mieloide/diagnóstico , Síndromes Mielodisplásicos/diagnóstico , Radioinmunoterapia/métodos , Acondicionamiento Pretrasplante/métodos , Enfermedad Aguda , Adolescente , Adulto , Anticuerpos Monoclonales/farmacología , Moléculas de Adhesión Celular , Femenino , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Leucemia Mieloide/complicaciones , Leucemia Mieloide/terapia , Depleción Linfocítica , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/terapia , Radioinmunoterapia/efectos adversos , Radioinmunoterapia/normas , Radioisótopos , Renio , Factores de Riesgo , Linfocitos T , Acondicionamiento Pretrasplante/efectos adversos , Resultado del TratamientoRESUMEN
Cancer-seeking antibodies (Abs) carrying radionuclides can be powerful drugs for delivering radiotherapy to cancer. As with all radiotherapy, undesired radiation dose to critical organs is the limiting factor. It has been proposed that optimization of radioimmunotherapy (RIT), that is, maximization of therapeutic efficacy and minimization of normal tissue toxicity, depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, using quantitative radionuclide imaging. Object-oriented software systems for estimating internal emitter radiation doses to the tissues of individual patients (patient-specific radiation dosimetry), using computer modules, are available for RIT, as well as for other radionuclide therapies. There is general agreement that radiation dosimetry (radiation absorbed dose distribution, cGy) should be utilized to establish the safety of RIT with a specific radiolabeled Ab in the early stages (i.e. phase I or II) of drug evaluation. However, it is less well established that radiation dose should be used to determine the radionuclide dose (amount of radioactivity, GBq) to be administered to a specific patient (i.e. radiation dose-based therapy). Although treatment planning for individual patients based upon tracer radiation dosimetry is an attractive concept and opportunity, particularly for multimodality RIT with intent to cure, practical considerations may dictate simpler solutions under some circumstances.
Asunto(s)
Radioinmunoterapia/normas , Radiometría/métodos , Protocolos Clínicos , Humanos , Neoplasias/radioterapiaRESUMEN
We have recently reported that a radioiodinated, DTPA-appended peptide, designated IMP-R1, is a residualizing iodine label that overcomes many of the limitations that have impeded the development of residualizing iodine for clinical use. In this study the potential of 131I-IMP-R1-RS7, an internalizing anti-EGP-1 monoclonal antibody, was evaluated by performing preclinical therapy studies in nude mice bearing Calu-3 human non-small cell carcinoma of the lung xenografis. Elimination of 6 of 9 established tumors (mean tumor volume=0.3 cm(3)) was observed using a single dose of 350 microCi/mouse of 131I-IMP-R1-RS7, with all animals tolerating the dose. At the same dose and specific activity of 131I-RS7, labeled using the conventional chloramine-T method, there were four deaths, and one complete remission in nine treated mice. At the maximum tolerated dose of conventionally 131I-labeled RS7, 275 microCi, mean stable disease for approximately 5 weeks was observed, with no complete responses. Specificity of the therapeutic effect was shown in an isotype-matched control experiment, where 131I-IMP-R1-RS7 was markedly more effective than the (131)I-IMP-R1-labeled control antibody. These studies demonstrate that (131)I-IMP-R1-RS7 provides a therapeutic advantage in comparison to conventional 131I-labeled RS7, as predicted by the increased tumor accretion observed previously in targeting studies. A direct comparison of the maximum tolerated doses of (131)I-IMP-R1-RS7 (350 microCi) and 90Y-DOTA-RS7 (105 microCi) was performed in this tumor model using large established tumors (mean tumor volume=0.85 cm(3)). Anti-tumor efficacy and toxicity of the two treatments were comparable.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/radioterapia , Neoplasias Pulmonares , Animales , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales/uso terapéutico , Relación Dosis-Respuesta en la Radiación , Evaluación Preclínica de Medicamentos , Humanos , Radioisótopos de Yodo/administración & dosificación , Radioisótopos de Yodo/uso terapéutico , Proteínas de la Membrana/inmunología , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Radioinmunoterapia/métodos , Radioinmunoterapia/normas , Trasplante Heterólogo , Resultado del TratamientoRESUMEN
188Re is one of the radioisotopes expected to emerge as useful for therapy. Development of new radiopharmaceuticals based on 188Re depends on the radiolabeling methods used, which would give stable complexes having predefined radiochemical properties and in vitro and in vivo stability. This paper has attempted to provide a perspective of 188Re-labeled monoclonal antibodies, their radiolabeling characteristics, methods for quality control of radioimmunoconjugates and in vitro stability for radioimmunotherapy of solid tumors. The direct method of 188Re radiolabeling of antibodies by reductive attachment of 188Re in which free sulfhydryl groups have been generated by reduction of the intramolecular S-S disulfide bonds has been shown to be a promising approach in particular. Moreover, excellent methods have been developed to test the radionuclide, radiochemical purity and stability of 188Re-radioimmunoconjugates using high performance liquid chromatography (HPLC) and paper chromatography.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Inmunoconjugados/uso terapéutico , Neoplasias/terapia , Radioinmunoterapia/métodos , Radioisótopos/uso terapéutico , Renio/uso terapéutico , Animales , Anticuerpos Monoclonales/aislamiento & purificación , Cromatografía Líquida de Alta Presión , Cromatografía en Papel , Estabilidad de Medicamentos , Humanos , Inmunoconjugados/aislamiento & purificación , Técnicas In Vitro , Ratones , Control de Calidad , Radioinmunoterapia/normas , Radioisótopos/aislamiento & purificación , Radioisótopos/normas , Renio/aislamiento & purificación , Renio/normasRESUMEN
While the conventional Medical Internal Radiation Dose (MIRD) approach is useful for estimating approximate organ absorbed doses in diagnostic applications of isotopes, this strategy is suited neither to the exacting requirements of targeted radionuclide therapy nor to radiopharmaceuticals with a non-uniform activity distribution. For the individual treatment planning of patients treated with common radionuclides emitting high energy betas, the individual activity distribution has to be obtained from CT-SPECT images and the doses to the target organs and critical tissues have to be calculated by point-kernel methods. Due to the stochastic nature, alpha-radioimmunotherapy (alpha-RIT) requires microdosimetric calculations with Monte Carlo on a realistic model of the source and target tissue at the micrometer level. For a prediction of the biological effects of intracellular labelling with Auger electron emitters an accurate subcellular modelling including the DNA structure at the nanometre level with knowledge of the target for the considered biological effect is necessary.
Asunto(s)
Células/efectos de la radiación , Radiometría/métodos , Radiometría/normas , Radioterapia/normas , 3-Yodobencilguanidina/uso terapéutico , Partículas alfa/uso terapéutico , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapéutico , Partículas beta/uso terapéutico , Médula Ósea/efectos de la radiación , Simulación por Computador , Femenino , Humanos , Transferencia Lineal de Energía , Masculino , Método de Montecarlo , Neuroblastoma/diagnóstico por imagen , Neuroblastoma/radioterapia , Valor Predictivo de las Pruebas , Radioinmunoterapia/normas , Radiofármacos/farmacocinética , Radiofármacos/uso terapéutico , Distribución Tisular , Tomografía Computarizada de Emisión de Fotón Único , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: Radioimmunotherapy (RIT) is a new therapeutic modality capable of systemic delivery of radionuclides specifically to sites of metastatic cancer. The L6 monoclonal antibody has been shown to target prostate cancer in preclinical studies and, along with chimeric L6 (ChL6), has been used for RIT in breast cancer patients. METHODS: Pharmacokinetics, blood counts, body weight, and antitumor activity of RIT with (90)yttrium-((90)Y)-DOTA-peptide-ChL6 (75-260 microCi) were determined in nude mice bearing human prostate cancer (PC3) xenografts. RESULTS: RIT produced durable, dose-dependent antitumor effects with a 100% response rate using 112 microCi and 150 microCi (the maximum tolerated dose) of (90)Y-DOTA-peptide-ChL6. Myelotoxicity was reversible, dose-limiting, and dose-related. RIT was associated with improved survival (P = 0.05). All 5 mice in the 150-microCi group survived the 84-day study period vs. 1/8 (13%) for untreated, tumored control mice. CONCLUSIONS: (90)Y-DOTA-peptide-ChL6 targets PC3 human prostate cancer xenografts in nude mice and has an antitumor effect. These results provide a basis for future RIT trials for patients with metastatic prostate cancer.
Asunto(s)
Compuestos Heterocíclicos/uso terapéutico , Oligopéptidos/uso terapéutico , Neoplasias de la Próstata/radioterapia , Radioinmunoterapia/normas , Radiofármacos/uso terapéutico , Itrio/uso terapéutico , Animales , Anticuerpos Monoclonales/uso terapéutico , Peso Corporal , Relación Dosis-Respuesta en la Radiación , Femenino , Compuestos Heterocíclicos/sangre , Compuestos Heterocíclicos/farmacocinética , Humanos , Recuento de Leucocitos , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Oligopéptidos/sangre , Oligopéptidos/farmacocinética , Recuento de Plaquetas , Radioinmunoterapia/efectos adversos , Radiofármacos/sangre , Radiofármacos/farmacocinética , Organismos Libres de Patógenos Específicos , Células Tumorales Cultivadas , Recuento Corporal Total , Itrio/sangre , Itrio/farmacocinética , Radioisótopos de Itrio/sangre , Radioisótopos de Itrio/farmacocinética , Radioisótopos de Itrio/uso terapéuticoRESUMEN
The use of monoclonal antibodies (mabs) in cancer therapy has gained renewed interest, due to recent reports of remarkable clinical response, particularly in patients with low-grade non-Hodgkin lymphoma. Better defined and more appropriate target antigens and "humanized" mabs, reducing the risk of inducing neutralising human anti-mouse antibodies, have contributed to the improvement in results. Conjugation of mabs with various radionuclides is now being explored as a means of further enhancing clinical efficacy, the idea being to allow systemic delivery of targeted radiation to areas of disease while sparing normal tissue. Radioimmunotherapy may be administered as a single large dose of radiolabelled mabs, usually requiring haematological stem cell support, or as multiple, smaller fractions. The criteria for the selection of mabs and radionuclides are discussed in the article, as are recent clinical data and the problems and prospects of future developments in radioimmunotherapy.
Asunto(s)
Radioinmunoterapia , Ensayos Clínicos como Asunto , Humanos , Radioinmunoterapia/métodos , Radioinmunoterapia/normas , Radioinmunoterapia/tendenciasRESUMEN
BACKGROUND: Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. METHODS: Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function, and no previous radiation. RESULTS: The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in < or =21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. CONCLUSIONS: Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Lutecio , Neoplasias Ováricas/radioterapia , Radioinmunoterapia/normas , Radioisótopos , Adulto , Anciano , Artralgia/etiología , Médula Ósea/patología , Médula Ósea/efectos de la radiación , Progresión de la Enfermedad , Relación Dosis-Respuesta en la Radiación , Femenino , Humanos , Inyecciones Intraperitoneales , Persona de Mediana Edad , Neoplasias Ováricas/sangre , Neoplasias Ováricas/patología , Recuento de Plaquetas , Radioinmunoterapia/efectos adversos , Radioinmunoterapia/métodosRESUMEN
UNLABELLED: The use of 67Cu-labeled antibodies for the treatment of cancer has advanced to the clinical trial phase. Quantitation of 67Cu radiopharmaceuticals is complicated by the presence of the radioimpurity of 64Cu in 67Cu supplies. Here we report a method to assay 67Cu and 64Cu in a mixed sample with a commonly available instrument, the ionization chamber dose calibrator. METHODS: The activities of 67Cu and 64Cu in a mixed sample can be calculated from a single-dose calibrator measurement. The calculation requires (1) instrument-specific response coefficients D67 and D64, generated by gauging the instrument for the efficiency of measurement of 67Cu and 64Cu, and (2) a value for the ratio of 67Cu to 64Cu in the sample, routinely provided by major suppliers of 67Cu. D67 and D64 were empirically determined by measuring samples containing known amounts of 67Cu and 64Cu. The samples were also assayed by gamma ray spectroscopy to verify the isotope ratios given by the suppliers. RESULTS: This method generated accurate response coefficients. At the recommended dose calibrator setting for the measurement of 67Cu, at which D67 = 1.0, the measurement for D67 with this method was 1.02 (+/- 0.04). Isotope ratios provided by the radionuclide suppliers were corroborated by gamma ray spectroscopy. CONCLUSION: A method is presented by which 67Cu and 64Cu in a mixed sample can be assayed using a dose calibrator. Although the derived numeric constants are only correct for a specific dose calibrator and setting, the method can be adapted for use with any dose calibrator.